There are 26 approved antiretroviral drugs available in 2012 in 6 mechanistic classes:
reverse transcripatase inhibitors (both nucleosides and non-nucleosides), protease
inhibitors, entry inhibitors (both fusion inhibitors and CCR5 receptor antagonists),
and integrase inhibitors. Current antiretroviral therapy combinations dramatically
decrease HIV-related morbidity and mortality. However, despite these advances, some
current antiretroviral regimens may be inconvenient, toxic, and/or have suboptimal
antiretroviral activity, particularly against drug-resistant viruses. Thus, newer
compounds are needed that improve convenience and tolerability, reduce toxicity, and
improve antiretroviral activity, particularly against drug-resistant viruses. Additionally,
new drugs may better penetrate tissue reservoirs (e.g. genital tract, central nervous
system), exploit new targets with new mechanisms of action, or be administered in
new formulations.
There are a number of HIV investigational drugs in development currently. These include
a new pharmacokinetic “boosting” agent, cobicistat (GS-9350) and newer antiretroviral
agents in a number of classes, including new nucleoside reverse transcriptase inhibitors,
non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors,
and integrase inhibitors. Of those in the pipeline, a few compounds are in advanced
stages of development: the nucleoside analogue GS-7340, a pro-drug of tenofovir (phase
2); and the integrase inhibitors, elvitegravir (phase 3 completed) and dolutegravir
(phase 3). In addition, there are drugs with new mechanisms of action in development,
including the CD4 attachment inhibitor, BMS-663068 (phase 2), and the CCR5 antagonist,
cenicriviroc (phase 2).
Probably the greatest need in the HIV clinic today is compounds that have activity
against multidrug-resistant viral strains. Another important need is alternative one-pill,
once-daily formulations for both initial and subsequent regimens. However, the clinical
use of these newer agents will depend on the results of phase 3 clinical trials, and
the timeline for development and availability.